Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy

Background: Clopidogrel and proton pump inhibitors (PPIs) are among the most used drugs in Denmark for which there exists pharmacogenomics (PGx)-based dosing guidelines and FDA annotations. In this study, we further scrutinized the use of clopidogrel and PPIs when prescriptions were redeemed from Da...

Descripción completa

Detalles Bibliográficos
Autores principales: Westergaard, Niels, Tarnow, Lise, Vermehren, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916548/
https://www.ncbi.nlm.nih.gov/pubmed/33578832
http://dx.doi.org/10.3390/metabo11020096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916548/
https://www.ncbi.nlm.nih.gov/pubmed/33578832
http://dx.doi.org/10.3390/metabo11020096

Ejemplares similares